Citations

Clear

1434 citation(s) found for "Uk, Nathan".

Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension
Naik‐Mathuria, Bindi , Dasgupta, Roshni , Short, Scott S. , Lovvorn, Harold N. , Newman, Erica, Rich, Barrie S. , Piché, Nelson , Glick, Richard D. , Petroze, Robin T. , Polites, Stephanie F. , Alore, Elizabeth , Sutthatarn, Pattamon , Wong‐Michalak, Shannon , Romao, Rodrigo , Al‐Hadidi, Ameer , Marquart, John , Gainer, Hailey, Johnson, Mike, Boehmer, Chloé , Rinehardt, Hannah , Seemann, Natashia M. , Davidson, Jacob , Polcz, Valerie E., Lund, Sarah , McKay, Katlyn G. , Correa, Hernán , Lund, Sarah B, Dasgupta, Roshni , Utria, Alan Fremder , Ehrlich, Peter F. , Aldrink, Jennifer H. , Murphy, Andrew J. , Lautz, Timothy B. , Kim, Eugene S. , Lal, Dave R. , Kastenberg, Zachary J. , Malek, Marcus M. , Whitlock, Richard S. , Chen, Stephanie , Rubalcava, Nathan S. , Gainer, Hailey, Rothstein, David H.

Mayo Clinic

Annals of Surgery | June 2, 2023 | Volume: 279 | Issue: 3 | Pages: 528-535

10.1097/sla.0000000000005921 | PMID 37264925 Get It

Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.
Radiologically Inserted Gastrostomy Tube Placement Guided by the Assessment and Primary Palliative Care Provided by an Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: A Single-Arm Retrospective Clinical Study
Parra‐Cantu, Carolina , Martinez‐Thompson, Jennifer M. , Linch, Forrest , Chou, Claudia Z., Pattinson, Adele K., Staff, Nathan P. , Neisen, Melissa , Linch, Forrest B , Neisen, Melissa , Staff, Nathan P , Welch, Tasha L.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | June 2, 2023 | Volume: 41 | Issue: 5 | Pages: 516-526

10.1177/10499091231180553 | PMID 37266922 Get It

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a median survival of about 3 years. An ALS multidisciplinary team can provide primary palliative care and improve outcomes and quality of life for patients. Feeding tube insertion may be considered for patients with significant weight loss, or respiratory insufficiency. While radiologically inserted gastrostomy (RIG) tube placement may be an option, further studies are required to determine its best timing and appropriateness. This study’s objectives were to evaluate the feasibility and outcomes of RIG tube placement in ALS patients over a 90-day follow-up period through the assessment and primary palliative care provided by the multidisciplinary team. This retrospective study reviewed the placement of 16 or 18 French RIG-tube without intubation or endoscopy for 36 ALS patients at a single center between April 2019 and December 2021. Measures included ALS Functional Rating Scale-Revised (ALSFRS-R) scores to determine the ALS stage. Demographic, clinical, procedural, and follow-up data were reviewed. Results showed that the RIG tube placement had a low rate of minor adverse events (11%) and no major procedure-related adverse events. The mean ALSFRS-R score at the time of procedure in subjects who died within 90 days was lower than of those alive beyond 90 days ( P = .04). This study found that RIG-tube placement is a safe and effective way to manage dysphagia in ALS patients and highlights the importance of educating members of the multidisciplinary clinic in palliative care principles to determine the appropriateness of RIG tube placement.
The Role of Remimazolam in Neurosurgery and in Patients With Neurological Diseases: A Narrative Review
Teixeira, Miguel T. , Brinkman, Nathan , Pasternak, Jeffrey J., Abcejo, Arnoley S.

Mayo Clinic

Journal of Neurosurgical Anesthesiology | June 2, 2023 | Volume: 36 | Issue: 1 | Pages: 11-19

10.1097/ana.0000000000000917 | PMID 37264540 Get It

Remimazolam is a novel ultrashort-acting benzodiazepine that produces sedation by acting as a positive allosteric modulator of the gamma-amino butyric acid-A receptor. Its high water solubility and metabolism via tissue esterases allow for a rapid onset of sedation/anesthesia and prompt arousal despite prolonged use. In addition, the effects of remimazolam can be reversed with flumazenil. This narrative review discusses the role of remimazolam in patients undergoing neurosurgical and neuroradiological procedures, specifically its role during awake craniotomies and compatibility with neuromonitoring. Considerations for remimazolam use in patients with neurological diseases are also highlighted. In addition, the impact of remimazolam on postoperative excitation, risk for postoperative delirium, and delayed neurocognitive recovery are discussed. Although there seems to be a clinical promise for remimazolam based on limited case studies and our own institutional experience of its use, further clinical investigation is warranted to understand the potential impact of remimazolam on surgical and neurological outcomes.
Incorporation of a biparietal narrowing metric to improve the ability of machine learning models to detect sagittal craniosynostosis with 2D photographs
Anderson, Megan, Jungbauer, Dana , Ahn, Edward S. , Stoltz, Petronella, Martin, Jonathan E. , Hersh, David S. , Anderson, Megan G., Leclair, Nathan K. , Bookland, Markus J.

Mayo Clinic

Neurosurgical Focus | June 1, 2023 | Volume: 54 | Issue: 6 | Pages: E9

10.3171/2023.3.focus2349 | PMID 37283444 Get It

OBJECTIVE Sagittal craniosynostosis is the most common form of craniosynostosis and typically results in scaphocephaly, which is characterized by biparietal narrowing, compensatory frontal bossing, and an occipital prominence. The cephalic index (CI) is a simple metric for quantifying the degree of cranial narrowing and is often used to diagnose sagittal craniosynostosis. However, patients with variant forms of sagittal craniosynostosis may present with a "normal" CI, depending on the part of the suture that is closed. As machine learning (ML) algorithms are developed to assist in the diagnosis of cranial deformities, metrics that reflect the other phenotypic features of sagittal craniosynostosis are needed. In this study the authors sought to describe the posterior arc angle (PAA), a measurement of biparietal narrowing that is obtained with 2D photographs, and elucidate the role of PAA as an adjuvant to the CI in characterizing scaphocephaly and the potential relevance of PAA in new ML model development. METHODS The authors retrospectively reviewed 1013 craniofacial patients treated during the period from 2006 to 2021. Orthogonal top-down photographs were used to calculate the CI and PAA. Distribution densities, receiver operating characteristic (ROC) curves, and chi-square analyses were used to describe the relative predictive utility of each method for sagittal craniosynostosis. RESULTS In total, 1001 patients underwent paired CI and PAA measurements and a clinical head shape diagnosis (sagittal craniosynostosis, n = 122; other cranial deformity, n = 565; normocephalic, n = 314). The area under the ROC curve (AUC) for the CI was 98.5% (95% confidence interval 97.8%–99.2%, p < 0.001), with an optimum specificity of 92.6% and sensitivity of 93.4%. The PAA had an AUC of 97.4% (95% confidence interval 96.0%–98.8%, p < 0.001) with an optimum specificity of 94.9% and sensitivity of 90.2%. In 6 of 122 (4.9%) cases of sagittal craniosynostosis, the PAA was abnormal while the CI was normal. This means that adding a PAA cutoff branch to a partition model increases the detection of sagittal craniosynostosis. CONCLUSIONS Both CI and PAA are excellent discriminators for sagittal craniosynostosis. Using an accuracy-optimized partition model, the addition of the PAA to the CI increased model sensitivity compared to using the CI alone. Using a model that incorporates both CI and PAA could assist in the early identification and treatment of sagittal craniosynostosis via automated and semiautomated algorithms that utilize tree-based ML models.
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis
Waters, Margo , Dobry, Allison S. , Le, Stephanie T. , Shinkai, Kanade , Beachkofsky, Thomas M. , Davis, Mark D.P. , Markova, Alina , Pasieka, Helena B. , Rosenbach, Misha , Seminario‐Vidal, Lucia , Trinidad, John , Altman, Emily , Arakaki, Ryan, Ardern‐Jones, Michael R. , Bridges, Alina G. , Cardones, Adela R. , Chen, Jennifer K. , Chen, Steven T. , Cheng, Kyle , Harp, Joanna, King, Brett , Lowenstein, Eve J. , Luxenberg, Erin, Mancuso, Jennifer , Mauskar, Melissa , Milam, Philip , Nelson, Caroline A. , Nguyen, Cuong V. , Nutan, Fnu, Patel, Tejesh , Rahnama‐Moghadam, Sahand , Rekhtman, Sergey , Rojek, Nathan W. , Sarihan, Mansi, Shaigany, Sheila , Sharma, Timmie R. , Shearer, Sabrina M, Shields, Bridget E. , Strowd, Lindsay C. , Tartar, Danielle , Walls, Andrew C., Ziemer, Carolyn, Kaffenberger, Benjamin H. , Nguyen, C V , Seminario-Vidal, L , Kaffenberger, B , Dominguez, Arturo Ricardo , Kroshinsky, Daniela , Micheletti, Robert , Mostaghimi, Arash , Albrecht, Joerg , Chadha, Angad , Daveluy, Steven , DeNiro, Katherine L. , Keller, Jesse Joel , Korman, Abraham Moris , Motaparthi, Kiran , Ortega‐Loayza, Alex G. , Shaigany, Sheila , Thomas, Cristina , Wanat, Karolyn A. , Walls, Andrew F. , Zaba, Lisa C. , Maverakis, Emanual Michael

Mayo Clinic

JAMA Dermatology | May 31, 2023 | Volume: 159 | Issue: 7 | Pages: 772

10.1001/jamadermatol.2023.1347 | PMID 37256599 Get It

Importance Scoring systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosis and are weighted toward comorbidities and systemic features; morphologic terminology for EN lesions is inconsistent. Objectives To establish consensus among expert dermatologists on EN terminology, morphologic progression, and most-affected sites, and to build a framework for developing a skin-directed scoring system for EN. Evidence Review A Delphi consensus using the RAND/UCLA appropriateness criteria was initiated with a core group from the Society of Dermatology Hospitalists to establish agreement on the optimal design for an EN cutaneous scoring instrument, terminology, morphologic traits, and sites of involvement. Findings In round 1, the 54 participating dermatology hospitalists reached consensus on all 49 statements (30 appropriate, 3 inappropriate, 16 uncertain). In round 2, they agreed on another 15 statements (8 appropriate, 7 uncertain). There was consistent agreement on the need for a skin-specific instrument; on the most-often affected skin sites (head and neck, chest, upper back, ocular mucosa, oral mucosa); and that blanching erythema, dusky erythema, targetoid erythema, vesicles/bullae, desquamation, and erosions comprise the morphologic traits of EN and can be consistently differentiated. Conclusions and Relevance This consensus exercise confirmed the need for an EN skin-directed scoring system, nomenclature, and differentiation of specific morphologic traits, and identified the sites most affected. It also established a baseline consensus for a standardized EN instrument with consistent terminology.
Pharmacologic and Other Noninvasive Treatments of the Aging Face: A Review of the Current Evidence
Bustos, Samyd S. , Vyas, Krishna S. , Huang, Tony Chieh‐Ting , Suchyta, Marissa , Wyles, Saranya P. , Bustos, S S , LeBrasseur, Nathan K. , Cotofana, Sebastian , Mardini, Samir

Mayo Clinic

Plastic & Reconstructive Surgery | May 30, 2023 | Volume: 154 | Issue: 4 | Pages: 829e-842e

10.1097/prs.0000000000010767 | PMID 39314107 Get It

Summary: Aging of the face is the result of the interrelation of three-dimensional changes occurring over time among the 5 different layers of the face and its associated structures. Knowledge regarding the causes of these changes and identification of new key anatomic structures have helped elucidate one of the most complex areas of the human body. This has resulted in the introduction of pharmacologic agents to help stop, mitigate, or counteract signs of aging and restore the youthful appearance of the face. The authors performed a systematic search of the literature to review the current highest-level evidence of facial antiaging pharmacologic agents. Pharmacologic and minimally invasive antiaging treatments can target different components of facial aging and continue to evolve. With continuous research efforts, traditional treatments, such as botulinum toxin type A, injectable fillers, and chemical peels, are emerging in newer, more effective formulations, with longer lasting clinical results. However, for soft-tissue descent and facial volume loss, surgery remains the standard treatment. An adequate understanding of the three-dimensional process of facial aging over time (the fourth dimension), facial anatomy, and the pharmacologic properties of antiaging/rejuvenation agents are the sine qua non of facial antiaging treatment. The specific modality should be tailored to patient characteristics, preferences, and goals.
181. Novel Method Of Double Innervated Free Gracilis Muscle Functional Transfer For Facial Reanimation
Boonipat, Thanapoom , Hebel, Nathan , Meaike, Jesse D. , Robertson, Carrie E. , Asaad, Malke , Mardini, Samir

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 18, 2023 | Volume: 11 | Issue: 5S | Pages: 113-114

10.1097/01.gox.0000938304.06228.9c Get It

117. Comparative Analysis of Two Hemiarthroplasty Techniques for Symptomatic Distal Radial Ulnar Joint
Hebel, Nathan , Helsper, Elizabeth, Wu, Kitty Y. , Hassan, Bassem El, Moran, Steven L. , Kakar, Sanjeev

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 18, 2023 | Volume: 11 | Issue: 5S | Pages: 73-74

10.1097/01.gox.0000938056.29406.f0 Get It

Pharmacogenomic panel testing provides insight and enhances medication management in people with HIV
Zeuli, John D. , Wright, Jessica , Kasten, Mary J. , Ragan, Ashley Kate, Rizza, Stacey A. , Temesgen, Zelalem , Vergidis, Paschalis , Wilson, John , Vergidis, Paschalis , Wright, Jessica A , Rivera, Christina G. , Mahmood, Maryam , Cummins, Nathan W.

Mayo Clinic

AIDS | May 18, 2023 | Volume: 37 | Issue: 10 | Pages: 1525-1533

10.1097/qad.0000000000003598 | PMID 37199600 Get It

Objective: Our study aimed to assess the impact of pharmacogenomic panel testing in people with HIV (PWH). Design: Prospective, observational intervention assessment Methods: One hundred PWH were provided a comprehensive pharmacogenomic panel during routine care visits within the HIV specialty clinic of a large academic medical center. The panel determined the presence of specific genetic variants that could predict response or toxicity to commonly prescribed antiretroviral therapy (ART) and non-ART medications. An HIV specialty pharmacist reviewed the results with participants and the care team. The pharmacist (1) recommended clinically actionable interventions based on the participants’ current drug therapy, (2) assessed for genetic explanations for prior medication failures, adverse effects, or intolerances, and (3) advised on potential future clinically actionable care interventions based on individual genetic phenotypes. Results: Ninety-six participants (median age 53 years, 74% white, 84% men, 89% viral load <50 copies/ml) completed panel testing, yielding 682 clinically relevant pharmacogenomic results (133 major, 549 mild–moderate). Ninety participants (89 on ART) completed follow-up visits with 65 (72%) receiving clinical recommendations based on current medication profiles. Of the 105 clinical recommendations, 70% advised additional monitoring for efficacy or toxicity, and 10% advised alteration of drug therapy. Panel results offered explanation for prior ART inefficacy in one participant and ART intolerance in 29%. Genetic explanation for non-ART toxicity was seen in 21% of participants, with genetic contributors to inefficacy of non-ART therapy identified in 39% of participants. Conclusion: Preliminary data in a small cohort of PWH demonstrates benefit of routine pharmacogenomic panel testing.
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Zarif, Talal El , Nassar, Amin H. , Adib, Elio , Fitzgerald, Bailey G. , Huang, Jiaming , Mouhieddine, Tarek H. , Rubinstein, P , Nonato, Taylor K., McKay, Rana R. , Li, Mingjia , Baiocchi, Robert A. , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazlı , Falohun, Adewunmi, Abdel‐Wahab, Noha , Diab, Adi , Bankapur, Anand, Reed, Alexandra, Kim, Chul , Arora, Aakriti, El‐Am, Edward , Abdallah, Wassim , Al‐Hader, Ahmad, Ghazal, Batool Abu, Drolen, Claire , Drakaki, Alexandra , Baena, Javier , Nebhan, Caroline A. , Haykal, Tarek , Morse, Michael A. , Cortellini, Alessio , Pinato, David J. , Pria, Alessia Dalla , Bakalov, Veli , Bahary, Nathan , Rajkumar, Aarthi , Mangla, Ankit , Singh, Parminder , Nana, Frank Aboubakar , Lopetegui‐Lia, Nerea , Dobbs, Ryan W. , Funchain, Pauline , Long, Georgina V. , Genova, Carlo , Barletta, Giulia, Idossa, Damé , Lamberti, Giuseppe , Freeman, Dory , Chiao, Elizabeth Y. , Johnson, Douglas B. , Ramaswami, Ramya , Bower, Mark , Emu, Brinda , Baden, Lindsey R. , Sonpavde, Guru , Naqash, Abdul Rafeh , El Zarif, Talal , Rubinstein, Paul G , Mittra, Arjun , Owen, Dwight H , Lorentsen, Michael , Dittus, Christopher , Dizman, Nazli , Abdel-Wahab, Noha , Diab, Adi , Kim, Chul , Shah, Neil J , Kozaily, Elie , Abdallah, Wassim , Saeed, Anwaar , Drolen, Claire , Lechner, Melissa G , Drakaki, Alexandra , Nebhan, Caroline A , Haykal, Tarek , Cortellini, Alessio , Pinato, David J , Dalla Pria, Alessia , Hall, Evan , Bahary, Nathan , Mangla, Ankit , Shah, Vishal , Aboubakar Nana, Frank , Lopetegui-Lia, Nerea , Dima, Danai , Dobbs, Ryan W , Funchain, Pauline , Woodford, Rachel , Long, Georgina V , Menzies, Alexander M , Genova, Carlo , Puri, Sonam , Florou, Vaia , Lamberti, Giuseppe , Addeo, Alfredo , Bersanelli, Melissa , Xie, Wanling , Reid, Erin G , Chiao, Elizabeth Y , Sharon, Elad , Johnson, Douglas B , Ramaswami, Ramya , Bower, Mark , Choueiri, Toni K , Lurain, Kathryn , Sonpavde, Guru , Naqash, Abdul Rafeh , Nassar, Amin H. , Singh, Parminder , Saeed, Anwaar , Shah, Vishal , Dima, Danai , Saleem, Rabia, Saponara, Maristella , Queirolo, Paola , Addeo, Alfredo , Xie, Wanling , Sharon, Elad , Marron, Thomas , Choueiri, Toni K. , Espinar, Javier Baena

Mayo Clinic

Journal of Clinical Oncology | May 16, 2023 | Volume: 41 | Issue: 21 | Pages: 3712-3723

10.1200/jco.22.02459 | PMID 37192435 Get It

PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.